As Pharma Deals Progress, Propeller Health Sharpens Its Strategy

Xconomy Wisconsin — 

By teaming up with larger, more established companies, startups can avoid having to reinvent the wheel—or, in the case of Propeller Health, the inhaler.

Madison, WI-based Propeller Health says that it and Boehringer Ingelheim, a German pharmaceutical giant whose products include the Respimat inhaler, have taken a key step forward in their joint effort to commercialize a version of the device that attaches to an add-on sensor developed by Propeller.

The two have now launched a new program aimed at providing these sensor-equipped inhalers to certain patients who already use the Respimat to treat asthma or chronic obstructive pulmonary disease (COPD). The sensors measure things like when and where patients are taking their medications, and are part of a system designed to provide caregivers data and help patients manage their conditions.

Joe Slavinsky, vice president of business development at Propeller, says the startup has led or co-led more than 40 commercial programs since launching in 2010, including one with Humana (NYSE: HUM), a major health insurer based in Louisville, KY. The new program with BI stands out because of the types of parties involved and their position along the development pipeline, he says.

“Other relationships you’ve seen in respiratory medicine with a digital health company and a pharma company have been focused mainly on tracking and clinical trials,” Slavinsky says. “This is different in that we’re selling Propeller’s solution directly to the market—directly to providers—with the help of BI.”

BI and Propeller first agreed to terms in September 2014, according to a report from the website MobiHealthNews. Then, about a year ago, the FDA gave Propeller the go-ahead to market its system—which combines sensors, mobile apps, software analytics, and patient-specific feedback—for use with COPD medications delivered by Respimat inhalers. One such drug is Spiriva—like Respimat, a BI product—which the FDA approved in September to also treat asthma.

The new program will enroll patients at “select U.S. health systems,” according to a press release. Slavinsky says that salespeople from Propeller and BI will work together to decide which organizations make the most sense to target, and that those with the largest numbers of patients who are prescribed Respimat-delivered medications are likely to rise to the top. Then, he says, the two companies will home in on individual patients using a simple, list-based method that Propeller has nonetheless found to be effective.

“This will be very similar to the way we currently sell our system,” Slavinsky says. “We go to these health systems, we get a list of patients, and then we’re able to contact patients from that list.”

A similar program could be the next step in Propeller’s partnership with another big pharma company, U.K.-based GlaxoSmithKline (NYSE: GSK). Announced in December, the tie-up somewhat resembles the BI-Propeller partnership in that it involves developing a custom sensor for—and making it work with—an inhaler that’s already on the market (in this case, the model is GSK’s Ellipta). Slavinsky says Propeller’s hope is that its work with GSK will eventually proceed toward commercialization, similar to the sequence with BI.

Even more recent was news of an agreement between Propeller and Aptar Pharma, part of Crystal Lake, IL-based AptarGroup (NYSE: ATR), to develop a connected inhaler from the ground up. Neither Propeller nor Aptar is a drugmaker—the latter company has for decades manufactured and supplied valves, stems, housings, and other components for inhalers. As a result, the two partners would need to license the new inhaler to a third-party pharma business, which would bring the device to market in combination with its medicine.

Slavinsky says that in the future, connected inhalers are likely to be integrated. That means … Next Page »

Single PageCurrently on Page: 1 2